To drive our continued development of novel drugs and successfully advance our drug development programs, we have developed a systematic and comprehensive in-house R&D engine comprising key technology platforms, a stringent R&D management system, an experienced R&D team and an extensive IP portfolio.
We have built an integrated in-house R&D platform supported by key technology platforms that cover the full life span of drug development, including our molecule design and druggability optimization platform, natural bioactive compound and lead compound discovery platform, efficacy evaluation platform, pharmacokinetic research platform, drug structure research platform, CMC research platform and pilot production platform.
We implement a stringent R&D management system focused on the one hand on first-in-class drug development, and on the other hand on rigorous assessment and validation starting from the early stages of drug development. Leveraging our technology platforms and capabilities, we strategically design drug assets and select drug programs to increase their success rates.
We have established an R&D team about hundred scientists as of the date of this prospectus, on our key assets since program initiation. At the helm of our research and development team is Dr. Peng Wang, our co-founder and chief research officer, as well as Dr. Yutai Li, our chief toxicology officer.
We foster an environment of open innovation, building upon a strong network of institutions, scientists, and clinical practitioner partners to source and collaborate on drug programs.
To date, we have established robust patent protection for each of our key novel drug candidates across China, the U.S., the EU, Japan and internationally through PCT. We continually assess our IP profile and strategically apply for patent protection for our drug candidates.
